Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.34 |
| ▸ | GBA1 | P04062 | 6/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25715688 | 0.89 | SMPD1 (0.42) | HRH4HRH3SMPD1GBA1 | |
| SCHEMBL19705718 | 0.87 | SMPD1 (0.48) | HRH4HRH3SMPD1GBA1 | |
| SCHEMBL10080835 | 0.85 | SMPD1 (0.50) | HRH4HRH3SMPD1GBA1 | |
| SCHEMBL19245614 | 0.85 | HRH4 (0.34) | HRH4HRH3SMPD1GBA1L3MBTL1 | |
| SCHEMBL13453642 | 0.84 | SMPD1 (0.41) | HRH4HRH3SMPD1GBA1 | |
| SCHEMBL7650649 | 0.83 | IDO1 (0.37) | HRH4HRH3 | |
| SCHEMBL17615109 | 0.82 | NAMPT (0.36) | HRH4HRH3IRAK4 | |
| SCHEMBL19086059 | 0.82 | NTRK1 (0.37) | HRH4HRH3SMPD1GBA1IRAK4 | |
| SCHEMBL18089449 | 0.82 | HRH4 (0.35) | HRH4HRH3SMPD1IRAK4 | |
| SCHEMBL12364362 | 0.82 | HRH4 (0.35) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024005460-A1 | COMPOUND COMPRISING SELF-IMMOLATIVE GROUP AND LIGAND-DRUG CONJUGATE COMPRISING SAME | 주식회사 트리오어 | 2024-01-04 | — | — | WO | disclosed |
| WO-2024005461-A1 | NOVEL LINKER COMPOUND AND LIGAND-DRUG CONJUGATE THEREFOR | 주식회사 트리오어 | 2024-01-04 | — | — | WO | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| US-20180133348-A1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2018-05-17 | — | — | US | disclosed |
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | HRH4 2715/4885HRH3 1777/4885SMPD1 1158/4885 |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | HRH4 4283/4885HRH3 4235/4885SMPD1 1460/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | HRH4 4283/4885HRH3 4235/4885SMPD1 1460/4885 |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | HRH4 2715/4885HRH3 1777/4885SMPD1 1158/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | HRH4 2830/4885HRH3 1828/4885SMPD1 1337/4885 |
| US-20180133348-A1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | CA9, CA14, CA13 | HRH4 1122/4885HRH3 856/4885SMPD1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.